Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:127555053" >
Teriflunomide reduc...
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use
-
O'Connor, PW (författare)
-
Lublin, FD (författare)
-
Wolinsky, JS (författare)
-
visa fler...
-
Confavreux, C (författare)
-
Comi, G (författare)
-
Freedman, MS (författare)
-
- Olsson, TP (författare)
- Karolinska Institutet
-
Miller, AE (författare)
-
Dive-Pouletty, C (författare)
-
Bego-Le-Bagousse, G (författare)
-
Kappos, L (författare)
-
visa färre...
-
(creator_code:org_t)
- 2013-07-14
- 2013
- Engelska.
-
Ingår i: Journal of neurology. - : Springer Science and Business Media LLC. - 1432-1459 .- 0340-5354. ; 260:10, s. 2472-2480
- Relaterad länk:
-
https://link.springe...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Multiple sclerosis (MS) relapses impose a substantial clinical and economic burden. Teriflunomide is a new oral disease-modifying therapy approved for the treatment of relapsing MS. We evaluated the effects of teriflunomide treatment on relapse-related neurological sequelae and healthcare resource use in a post hoc analysis of the Phase III TEMSO study. Confirmed relapses associated with neurological sequelae [defined by an increase in Expanded Disability Status Scale/Functional System (sequelae-EDSS/FS) ≥30 days post relapse or by the investigator (sequelae-investigator)] were analyzed in the modified intention-to-treat population (n = 1086). Relapses requiring hospitalization or intravenous (IV) corticosteroids, all hospitalizations, emergency medical facility visits (EMFV), and hospitalized nights for relapse were also assessed. Annualized rates were derived using a Poisson model with treatment, baseline EDSS strata, and region as covariates. Risks of sequelae and hospitalization per relapse were calculated as percentages and groups were compared with a χ2 test. Compared with placebo, teriflunomide reduced annualized rates of relapses with sequelae-EDSS/FS [7 mg by 32 % (p = 0.0019); 14 mg by 36 % (p = 0.0011)] and sequelae-investigator [25 % (p = 0.071); 53 % (p < 0.0001)], relapses leading to hospitalization [36 % (p = 0.015); 59 % (p < 0.0001)], and relapses requiring IV corticosteroids [29 % (p = 0.001); 34 % (p = 0.0003)]. Teriflunomide-treated patients spent fewer nights in hospital for relapse (p < 0.01). Teriflunomide 14 mg also decreased annualized rates of all hospitalizations (p = 0.01) and EMFV (p = 0.004). The impact of teriflunomide on relapse-related neurological sequelae and relapses requiring healthcare resources may translate into reduced healthcare costs.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
O'Connor, PW
-
Lublin, FD
-
Wolinsky, JS
-
Confavreux, C
-
Comi, G
-
Freedman, MS
-
visa fler...
-
Olsson, TP
-
Miller, AE
-
Dive-Pouletty, C
-
Bego-Le-Bagousse ...
-
Kappos, L
-
visa färre...
- Artiklar i publikationen
-
Journal of neuro ...
- Av lärosätet
-
Karolinska Institutet